vs
Side-by-side financial comparison of Intel (INTC) and Thermo Fisher Scientific (TMO). Click either name above to swap in a different company.
Intel is the larger business by last-quarter revenue ($13.6B vs $11.0B, roughly 1.2× Thermo Fisher Scientific). Thermo Fisher Scientific runs the higher net margin — 15.0% vs -6.5%, a 21.6% gap on every dollar of revenue. On growth, Intel posted the faster year-over-year revenue change (7.0% vs 6.2%). Thermo Fisher Scientific produced more free cash flow last quarter ($825.0M vs $-2.0B). Over the past eight quarters, Intel's revenue compounded faster (2.9% CAGR vs 2.2%).
Intel Corporation is an American multinational technology company headquartered in Santa Clara, California. It designs, manufactures, and sells computer components such as central processing units (CPUs) and related products for business and consumer markets. Intel was the world's third-largest semiconductor chip manufacturer by revenue in 2024 and has been included in the Fortune 500 list of the largest United States corporations by revenue since 2007.
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006.
INTC vs TMO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.6B | $11.0B |
| Net Profit | $-887.0M | $1.7B |
| Gross Margin | 34.4% | — |
| Operating Margin | — | 16.9% |
| Net Margin | -6.5% | 15.0% |
| Revenue YoY | 7.0% | 6.2% |
| Net Profit YoY | -382.6% | 9.6% |
| EPS (diluted) | $-0.73 | $4.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $13.6B | $11.0B | ||
| Q4 25 | $13.7B | $12.2B | ||
| Q3 25 | $13.7B | $11.1B | ||
| Q2 25 | $12.9B | $10.9B | ||
| Q1 25 | $12.7B | $10.4B | ||
| Q4 24 | $14.3B | $11.4B | ||
| Q3 24 | $13.3B | $10.6B | ||
| Q2 24 | $12.8B | $10.5B |
| Q1 26 | $-887.0M | $1.7B | ||
| Q4 25 | $-591.0M | $2.0B | ||
| Q3 25 | $4.1B | $1.6B | ||
| Q2 25 | $-2.9B | $1.6B | ||
| Q1 25 | $-821.0M | $1.5B | ||
| Q4 24 | $-126.0M | $1.8B | ||
| Q3 24 | $-16.6B | $1.6B | ||
| Q2 24 | $-1.6B | $1.5B |
| Q1 26 | 34.4% | — | ||
| Q4 25 | 36.1% | — | ||
| Q3 25 | 38.2% | — | ||
| Q2 25 | 27.5% | — | ||
| Q1 25 | 36.9% | — | ||
| Q4 24 | 39.2% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 35.4% | — |
| Q1 26 | — | 16.9% | ||
| Q4 25 | 4.2% | 18.5% | ||
| Q3 25 | 5.0% | 17.5% | ||
| Q2 25 | -24.7% | 16.9% | ||
| Q1 25 | -2.4% | 16.6% | ||
| Q4 24 | 2.9% | 17.7% | ||
| Q3 24 | -68.2% | 17.3% | ||
| Q2 24 | -15.3% | 17.3% |
| Q1 26 | -6.5% | 15.0% | ||
| Q4 25 | -4.3% | 16.1% | ||
| Q3 25 | 29.8% | 14.5% | ||
| Q2 25 | -22.7% | 14.9% | ||
| Q1 25 | -6.5% | 14.6% | ||
| Q4 24 | -0.9% | 16.0% | ||
| Q3 24 | -125.3% | 15.4% | ||
| Q2 24 | -12.5% | 14.7% |
| Q1 26 | $-0.73 | $4.43 | ||
| Q4 25 | $-0.10 | $5.21 | ||
| Q3 25 | $0.90 | $4.27 | ||
| Q2 25 | $-0.67 | $4.28 | ||
| Q1 25 | $-0.19 | $3.98 | ||
| Q4 24 | $-0.03 | $4.78 | ||
| Q3 24 | $-3.88 | $4.25 | ||
| Q2 24 | $-0.38 | $4.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.8B | $3.3B |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $125.0B | $51.9B |
| Total Assets | $205.3B | $113.3B |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $32.8B | $3.3B | ||
| Q4 25 | $14.3B | $10.1B | ||
| Q3 25 | $11.1B | $3.5B | ||
| Q2 25 | $9.6B | $6.4B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | $8.2B | $5.6B | ||
| Q3 24 | — | $6.6B | ||
| Q2 24 | — | $8.8B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $46.6B | $35.9B | ||
| Q3 25 | — | $31.9B | ||
| Q2 25 | — | $33.0B | ||
| Q1 25 | — | $31.4B | ||
| Q4 24 | $50.0B | $29.1B | ||
| Q3 24 | — | $31.2B | ||
| Q2 24 | — | $30.3B |
| Q1 26 | $125.0B | $51.9B | ||
| Q4 25 | $114.3B | $53.4B | ||
| Q3 25 | $106.4B | $51.0B | ||
| Q2 25 | $97.9B | $50.5B | ||
| Q1 25 | $99.8B | $49.4B | ||
| Q4 24 | $99.3B | $49.6B | ||
| Q3 24 | $99.5B | $49.0B | ||
| Q2 24 | $115.2B | $47.4B |
| Q1 26 | $205.3B | $113.3B | ||
| Q4 25 | $211.4B | $110.3B | ||
| Q3 25 | $204.5B | $103.0B | ||
| Q2 25 | $192.5B | $101.2B | ||
| Q1 25 | $192.2B | $99.0B | ||
| Q4 24 | $196.5B | $97.3B | ||
| Q3 24 | $193.5B | $100.4B | ||
| Q2 24 | $206.2B | $98.5B |
| Q1 26 | 0.02× | — | ||
| Q4 25 | 0.41× | 0.67× | ||
| Q3 25 | — | 0.62× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 0.64× | ||
| Q4 24 | 0.50× | 0.59× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.64× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $1.2B |
| Free Cash FlowOCF − Capex | $-2.0B | $825.0M |
| FCF MarginFCF / Revenue | -14.8% | 7.5% |
| Capex IntensityCapex / Revenue | 36.6% | — |
| Cash ConversionOCF / Net Profit | — | 0.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.6B | $6.8B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.3B | $3.5B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.0B | $1.4B | ||
| Q1 25 | $813.0M | $723.0M | ||
| Q4 24 | $3.2B | $3.3B | ||
| Q3 24 | $4.1B | $2.2B | ||
| Q2 24 | $2.3B | $2.0B |
| Q1 26 | $-2.0B | $825.0M | ||
| Q4 25 | $800.0M | $3.0B | ||
| Q3 25 | $121.0M | $1.8B | ||
| Q2 25 | $-1.5B | $1.1B | ||
| Q1 25 | $-4.4B | $361.0M | ||
| Q4 24 | $-2.7B | $2.8B | ||
| Q3 24 | $-2.4B | $1.9B | ||
| Q2 24 | $-3.4B | $1.7B |
| Q1 26 | -14.8% | 7.5% | ||
| Q4 25 | 5.9% | 24.5% | ||
| Q3 25 | 0.9% | 16.5% | ||
| Q2 25 | -11.7% | 10.2% | ||
| Q1 25 | -34.5% | 3.5% | ||
| Q4 24 | -18.7% | 24.7% | ||
| Q3 24 | -18.1% | 17.9% | ||
| Q2 24 | -26.4% | 15.7% |
| Q1 26 | 36.6% | — | ||
| Q4 25 | 25.5% | 3.8% | ||
| Q3 25 | 17.8% | 3.6% | ||
| Q2 25 | 27.6% | 2.7% | ||
| Q1 25 | 40.9% | 3.5% | ||
| Q4 24 | 40.9% | 4.2% | ||
| Q3 24 | 48.6% | 2.6% | ||
| Q2 24 | 44.3% | 2.9% |
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | 1.75× | ||
| Q3 25 | 0.63× | 1.39× | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 1.80× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INTC
| Intel Products | $12.8B | 94% |
| All other | $600.0M | 4% |
TMO
| Laboratory Products and Biopharma Services | $6.0B | 55% |
| Life Sciences Solutions | $2.6B | 24% |
| Analytical Instruments | $1.7B | 16% |
| Specialty Diagnostics | $1.1B | 10% |
